Faron Pharmaceuticals Ltd. Announces Collaboration With Turku PET Centre On Development Of Novel Cancer Immunotherapy
Research Grant from Tekes to Fund Project
TURKU – FINLAND, 30 June 2015 - Faron Pharmaceuticals Ltd. ("Faron"), the clinical stage biopharmaceutical company, announced today a collaboration with the Turku PET Center, one of the largest centers in Europe, on the development of its novel cancer immunotherapy Clevegen. Clevegen targets a proprietary cell surface receptor called Clever-1. A research grant from Tekes, the Finnish Technology and Development Center, will fund the project.
The PET (positron emission tomography) project will assist Faron in the design of an optimal use of Clevegen for cancer treatment, as well as guide diagnosis, pre-clinical and clinical development and measure potentially novel clinical end points to demonstrate efficacy. Clever-1 is an adhesion, scavenging and signaling molecule involved in cancer growth and is found in lymphatic and vascular endothelium as well as type 2 immunosuppressive macrophages.
The main strengths of PET are high sensitivity, functional nature of imaging and unique tracers that can provide information about cellular processes. Due to very high sensitivity PET can visualize receptors, gene expression and molecular pathways in patients with various diseases.
Markku Jalkanen, CEO of Faron Pharmaceuticals, said: “We are very pleased to be working with one of Europe’s leading PET Centers on the development of our proprietary cancer immunotherapy programme (Clevegen), which aims to control tumour immunity and cancer growth and spread. PET imaging is increasingly used to analyse diseases, such as cancer and Alzheimer’s disease, which involve complex remodeling of tissues in order to judge and design specific treatment regimens for patients.”
“Cancer is a leading cause of death worldwide and there continues to be a high unmet need for additional products and treatments, especially for patients with recurrent tumours or cancer types that are resistant to current therapeutic alternatives. We believe there is significant opportunity for Clevegen as a potential treatment for certain types of cancers.”
For more information contact:
Markku Jalkanen, CEO, Faron Pharmaceuticals
Phone: +358-40-520-6124
E-mail: markku.jalkanen@faronpharmaceuticals.com
Hume Brophy
Mary Clark, Supriya Mathur, Hollie Vile
Phone: +44 203 440 5654
E-mail: faron@humebrophy.com
Notes to Editors
About Clevegen-programme
Faron’s Clevegen program targets a proprietary cell surface receptor called Clever-1 (or Stabilin-1). Both in vitro and in vivo experimental work have demonstrated that the Clever-1 function blocking antibodies have significant impact on tumor immunity by reducing the number of tumor immunity suppressive cells. This change in tumor immunity venue drives tumor cell apoptosis as illustrated in the enclosed figure.
About Faron Pharmaceuticals, Ltd.
Faron Pharmaceuticals, Ltd. is a late clinical stage drug development company based in Turku, Finland. Faron has three major drug development projects focusing on acute lung injury, cancer growth and spread, and vascular inflammatory diseases. Faron’s lead product Traumakine to treat lung inflammation in ARDS patients is moving to a pan-European pivotal Phase III study in 2015. Faron has a pipeline of early stage assets including pre-clinical anti-Clever-1 antibody program on tumour immunity (Clevegen), Faron’s second drug development project.www.faronphamaceuticals.com
Help employers find you! Check out all the jobs and post your resume.
TURKU – FINLAND, 30 June 2015 - Faron Pharmaceuticals Ltd. ("Faron"), the clinical stage biopharmaceutical company, announced today a collaboration with the Turku PET Center, one of the largest centers in Europe, on the development of its novel cancer immunotherapy Clevegen. Clevegen targets a proprietary cell surface receptor called Clever-1. A research grant from Tekes, the Finnish Technology and Development Center, will fund the project.
The PET (positron emission tomography) project will assist Faron in the design of an optimal use of Clevegen for cancer treatment, as well as guide diagnosis, pre-clinical and clinical development and measure potentially novel clinical end points to demonstrate efficacy. Clever-1 is an adhesion, scavenging and signaling molecule involved in cancer growth and is found in lymphatic and vascular endothelium as well as type 2 immunosuppressive macrophages.
The main strengths of PET are high sensitivity, functional nature of imaging and unique tracers that can provide information about cellular processes. Due to very high sensitivity PET can visualize receptors, gene expression and molecular pathways in patients with various diseases.
Markku Jalkanen, CEO of Faron Pharmaceuticals, said: “We are very pleased to be working with one of Europe’s leading PET Centers on the development of our proprietary cancer immunotherapy programme (Clevegen), which aims to control tumour immunity and cancer growth and spread. PET imaging is increasingly used to analyse diseases, such as cancer and Alzheimer’s disease, which involve complex remodeling of tissues in order to judge and design specific treatment regimens for patients.”
“Cancer is a leading cause of death worldwide and there continues to be a high unmet need for additional products and treatments, especially for patients with recurrent tumours or cancer types that are resistant to current therapeutic alternatives. We believe there is significant opportunity for Clevegen as a potential treatment for certain types of cancers.”
For more information contact:
Markku Jalkanen, CEO, Faron Pharmaceuticals
Phone: +358-40-520-6124
E-mail: markku.jalkanen@faronpharmaceuticals.com
Hume Brophy
Mary Clark, Supriya Mathur, Hollie Vile
Phone: +44 203 440 5654
E-mail: faron@humebrophy.com
Notes to Editors
About Clevegen-programme
Faron’s Clevegen program targets a proprietary cell surface receptor called Clever-1 (or Stabilin-1). Both in vitro and in vivo experimental work have demonstrated that the Clever-1 function blocking antibodies have significant impact on tumor immunity by reducing the number of tumor immunity suppressive cells. This change in tumor immunity venue drives tumor cell apoptosis as illustrated in the enclosed figure.
About Faron Pharmaceuticals, Ltd.
Faron Pharmaceuticals, Ltd. is a late clinical stage drug development company based in Turku, Finland. Faron has three major drug development projects focusing on acute lung injury, cancer growth and spread, and vascular inflammatory diseases. Faron’s lead product Traumakine to treat lung inflammation in ARDS patients is moving to a pan-European pivotal Phase III study in 2015. Faron has a pipeline of early stage assets including pre-clinical anti-Clever-1 antibody program on tumour immunity (Clevegen), Faron’s second drug development project.www.faronphamaceuticals.com
Help employers find you! Check out all the jobs and post your resume.